secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0000950170-23-002622
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma General Counsel Christopher Ozeroff to depart effective March 31, 2023
--------------------------------------------------------------------------------

- Christopher D. Ozeroff, Secretary, SVP and General Counsel, to leave ARCA biopharma effective March 31, 2023.
- Departure is mutual and not due to any disagreement with the company's operations or policies.
- Will receive severance payments and COBRA reimbursement under existing employment agreement, conditioned on release of claims.
- No replacement for General Counsel has been announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000095017023002622/0000950170-23-002622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000095017023002622/abio-20230210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer